Navigation Links
Filling a Niche -- Role of Rb in Mammalian Stem Cells

Drs. Gustavo Leone and Michael Robinson (Ohio State University) and colleagues uncover a stem-cell specific role for the well-known tumor suppressor gene// , Rb, in the developing mammalian embryo.

Researchers had previously shown that mice deficient in Rb die as embryos. Using a combination of sophisticated mouse genetics and 3D computer modeling, OSU scientists have now determined why: Rb is required for the maintenance of the trophoblast stem cell population, which is essential for forming the placenta. Specific loss of Rb in trophoblast stem cells results in an overexpansion of trophoblast cells, aberrant placental formation, and embryonic death.

These findings implicate a role for the Rb pathway in the development of the human placenta and may provide a link between Rb, and possibly other cell cycle regulators, and pregnancy-related complications such as miscarriages and pre-eclempsia.

The demonstration that Rb tumor suppressor function is critical in trophoblast stem cells of the placenta will also certainly fuel the emerging hypothesis that stem-like cells may serve as a repository in which tumor suppressor function is critical to prevent cancer.

Source-Eurekalert
'"/>




Page: 1

Related medicine news :

1. Safety Of Dental Amalgam Fillings To Be Reviewed
2. First Major Study of Mammalian “Disorderly” Proteis
3. Cannibalistic Signals Help Mammalian Embryos Develop Normally
4. Blood Cells Capable of Regenerating Liver
5. White Cells Count Can Predict Heart Attack Death Risk
6. Gene Therapy Destroys Pancreatic Cancer Cells
7. Stem Cells Have Few Mutations
8. Heart may pull Cells from Body to Self-repair
9. Cells critical for asthma development found
10. Vitamin D Wipes out Cancer Cells
11. Bone Marrow Cells Help Heart Attack Patients
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Filling Niche Role Mammalian Stem Cells

(Date:8/8/2008)... Abnormal beating a marker for those most likely t...ug. 8 (HealthDay News) -- Abnormal heart rate turb...k for sudden death in patients with congestive hea...blished in the August HeartRhythm Journal , is th...ortality and heart failure progression, as well as...
(Date:8/8/2008)... MOUNT LAUREL, N.J., Aug. 8 /PRNewswire-FirstC... Medical Transcription Service Organization,(MTSO)... quarter ended June,30, 2008. Revenue for the seco... $88.7 million in the second quarter of 2007. The ... prior year period was primarily due to,customer l...
(Date:8/8/2008)..., FINDINGS:, UCLA and Intrinsic LifeSciences, a ...hod to measure the hormone, hepcidin, which regula...ution in the body. This new blood test will help...llions of people worldwide such as anemias and iro...will measure the amount of hepcidin in the blood. ...
(Date:8/8/2008)..., WINSTON-SALEM, N.C.Researchers at Wake Forest U...esearching how a lack of trust in formal medicine ...lity rates in Latino HIV patients than in white HI...st and Mistrust of Evidence-Based Medicine Among L... for AIDS Research (amfAR) and is expected to begi...
Breaking Medicine News(10 mins):Health News:MedQuist Reports Second Quarter 2008 Results 2Health News:MedQuist Reports Second Quarter 2008 Results 3Health News:MedQuist Reports Second Quarter 2008 Results 4Health News:MedQuist Reports Second Quarter 2008 Results 5Health News:MedQuist Reports Second Quarter 2008 Results 6Health News:MedQuist Reports Second Quarter 2008 Results 7Health News:MedQuist Reports Second Quarter 2008 Results 8Health News:MedQuist Reports Second Quarter 2008 Results 9Health News:Researchers to begin study aimed at helping Latino HIV patients 2
...me of lifting, bending and normal wear and tear.//...o relieve stress while going about your daily acti...r in arthritis care. If you’ve lived long enough, ... shoulder, elbow and wrist can cause pain, swellin...
... A protein called Human beta defensin 4 (HBD4) is ... present through out the body and helps it to figh...t this could be produced by genetically modified s...f researchers led by Dorothy Supp, a researcher an...
... Prevention has reported that many have come down ...requiring// hospital admission. The number of pat...utbreak. Explaining the extent of impact, CDC sa...isted in 67 hospitals spanning 18 districts and co...
...dreaded flu or influenza is just a step away; from...03 released// the FluMist, a popular influenza vir...t which has been approved by the Food and Drug A...same name FluMist, or by its clinical name CAIV-T ...
Other Medicine News:Health News:Nine Ways to Relieve Joint Stress 2
(Date:8/8/2008)...urkhalter, BOSTON, Aug. 8 /- Francis...dant fruit beverage every day could help protect,h...out after participating,in a clinical trial near h...cted by Bell Ventures, shows that after just 7 day...iovascular disease (CVD),was significantly reduce...
(Date:8/8/2008)...Innocoll, Inc., a privately-held,biopharmaceutical... dosed,in the first of three ongoing phase 2 clini...y, Innocoll Technologies Ltd, to investigate,Colla...ent of,post-operative pain., Innocoll,s BUPIVACAI...ioresorbable matrix of purified fibrillar collagen...
(Date:8/7/2008)...-- ProteoTech Inc. (ProteoTech),today announced th... Drug,(IND) requirements and has been cleared by t...l on Exebryl-1(R), a novel small molecule drug tar... the treatment of Alzheimer,s,disease. ProteoTech ...., At the 2008 International Conference on Alzhei...
(Date:8/7/2008)...ical Trial of ALXN6000 in Cancer, CHESHIRE, Conn....euticals, Inc. (Nasdaq: ALXN ) today announced th... Patent Number 7,408,041 titled,"Polypeptides and...mia,Cells and Uses Thereof." The patent is assigne...e composition-of-matter of Alexion,s anti-CD200,hu...
Breaking Medicine Technology:ViaViente Demonstrates Cardiovascular Benefits in New Human Trial 2ViaViente Demonstrates Cardiovascular Benefits in New Human Trial 3Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain 2Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain 3Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain 4ProteoTech's Exebryl-1(R) Enters Human Clinical Trials for the Treatment of Alzheimer's Disease 2Alexion Secures U.S. Patent for ALXN6000, a First-In-Class Anti-CD200 Monoclonal Antibody 2Alexion Secures U.S. Patent for ALXN6000, a First-In-Class Anti-CD200 Monoclonal Antibody 3Alexion Secures U.S. Patent for ALXN6000, a First-In-Class Anti-CD200 Monoclonal Antibody 4LifeNet Health and IMS Announce Partnership 1979 1LifeNet Health and IMS Announce Partnership 1979 2Clinical Data Presented on OrthoGlide 28R 29 Medial Knee Implant 932 1Clinical Data Presented on OrthoGlide 28R 29 Medial Knee Implant 932 2Immunosyn Announces Biozyme Labs Receipt of MHRA Manufacturing License Approval in Europe for the Biopharmaceutical SF 1019 929 1Immunosyn Announces Biozyme Labs Receipt of MHRA Manufacturing License Approval in Europe for the Biopharmaceutical SF 1019 929 2Immunosyn Announces Biozyme Labs Receipt of MHRA Manufacturing License Approval in Europe for the Biopharmaceutical SF 1019 929 3National Heart Lung and Blood Institute creates national network to study cardiovascular disease 7110 1National Heart Lung and Blood Institute creates national network to study cardiovascular disease 7110 2
Straight shafts with 4 mm jaws. Serrated handle with dull finish. Jaws straight.
Double-ended. 10 mm sickle shaped blade. 27 mm blunt, curved double-edged blade.
25 mm blunt, double-edged blade. Flat handle.
Fixed smooth rod which slides on skin. Designated most popular model or size.
Medicine Products: